Novartis Ireland Limited

Lobbying Organisation Novartis Ireland Limited

Date published 20 May, 2018

Relevant Matter Legislation

Public Policy Area Health

Period 1 Jan, 2018 to 30 Apr, 2018

Specific Details Strong Intellectual Property protection is a critical pre-requisite to maintaining an environment where innovation can thrive in healthcare

Intended results The European Commission is carrying out reviews of various aspects of IP incentives and protections for medicines. A large concern is the proposal to adopt a manufacturing waiver for SPCs (Supplementary Protection Certificates). We ask the EU’s current IP incentives framework is maintained.

Name of person primarily responsible for lobbying on this activity Susanne O'Reilly, Government Affairs Novartis, with Oliver O'Connor, CEO IPHA (Irish pharmaceutical Healthcare Association)

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) Yes

Current or Former Designated Public Official(s)

Oliver O'Connor (Former DPO) Special Advisor (Department of Health)

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Meeting at Novartis Ringaskiddy Campus. Importance of Intellectual Property (IP) to Medical Innovation Effect of the Supplementary Protection Certificate (SPC) on Employment Importance of IP to the Irish economy Effect of IP on patients

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Deirdre Clune MEP (European Parliament)